Kura Oncology stock maintains Market Outperform rating at Citizens JMP

Investing.com - Citizens JMP reiterated its Market Outperform rating and $24.00 price target on Kura Oncology (NASDAQ:KURA) stock, highlighting the company’s progress in clinical trials. According to InvestingPro data, analyst targets range from $11 to $40, with the stock showing strong momentum with an 8.86% gain last week.

The firm noted that Kura Oncology and Kyowa Kirin have dosed the first patient in the pivotal Phase 3 KOMET-017 trial, which evaluates ziftomenib in combination with intensive and non-intensive regimens for newly diagnosed NPM1-mutant or KMT2A-rearranged AML.

The trial consists of two global, randomized, double-blind studies with dual primary endpoints designed to support potential accelerated and full U.S. approval for the treatment.

Citizens JMP pointed out that ziftomenib remains on track for approval in the fourth quarter of 2025, with a PDUFA date of November 30, and new proof of concept data is expected at the 2025 ESMO congress.

The firm estimates Kura’s pro forma cash position at $730.7 million, which includes a projected $100 million milestone payment, while the company’s stock currently trades at a pro forma enterprise value of $64.4 million as it approaches commercialization of its first drug. With a market capitalization of $778.57 million and a solid balance sheet showing more cash than debt, Kura demonstrates strong financial positioning. For deeper insights into Kura’s financial health and detailed analysis, check out the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Kura Oncology reported a significant shortfall in its Q2 2025 financial results. The company announced revenues of $15.3 million, falling short of the projected $39.1 million, a 60.88% discrepancy. Additionally, the earnings per share (EPS) showed a loss of $0.75, which was worse than the anticipated loss of $0.41. Following these financial results, Citizens JMP adjusted its price target for Kura Oncology from $28.00 to $24.00, while maintaining a Market Outperform rating. Meanwhile, Guggenheim initiated coverage on Kura Oncology with a Neutral rating, pointing out competitive challenges in the AML market due to Syndax Pharmaceuticals’ presence. Kura Oncology is set to present preliminary clinical data for its drug darlifarnib at an upcoming medical congress, with preclinical research suggesting it may enhance the efficacy of certain cancer therapies. Citizens JMP reiterated its positive outlook on Kura Oncology, highlighting the potential of its compound KO-2806 in overcoming resistance to targeted therapies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.